Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agents
Mycoses · 2024-01 · 67 (1)
DOI: 10.1111/myc.13683 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Mycoses, online erschienen am 03.01.2024. Verfasst von Aditya K Gupta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mediprobe Research Inc., London, Ontario, Canada. Hauptthemen laut MEDLINE: Antifungal Agents, Onychomycosis. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
A growing body of literature has marked the emergence and spread of antifungal resistance among species of Trichophyton , the most prevalent cause of toenail and fingernail onychomycosis in the United States and Europe. We review published data on rates of oral antifungal resistance among Trichophyton species; causes of antifungal resistance and methods to counteract it; and in vitro data on the role of topical antifungals in the treatment of onychomycosis. Antifungal resistance among species of Trichophyton against terbinafine and itraconazole—the two most common oral treatments for onychomycosis and other superficial fungal infections caused by dermatophytes—has been detected around the globe. Fungal adaptations, patient characteristics (e.g., immunocompromised status; drug–drug interactions), and empirical diagnostic and treatment patterns may contribute to reduced antifungal efficacy and the development of antifungal resistance. Antifungal stewardship efforts aim to ensure proper antifungal use to limit antifungal resistance and improve clinical outcomes. In the treatment of onychomycosis, critical aspects of antifungal stewardship include proper identification of the fungal infection prior to initiation of treatment and improvements in physician and patient education. Topical ciclopirox, efinaconazole and tavaborole, delivered either alone or in combination with oral antifungals, have demonstrated efficacy in vitro against susceptible and/or resistant isolates of Trichophyton species, with low potential for development of antifungal resistance. Additional real‐world long‐term data are needed to monitor global rates of antifungal resistance and assess the efficacy of oral and topical antifungals, alone or in combination, in counteracting antifungal resistance in the treatment of onychomycosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mediprobe Research Inc., London, Ontario, Canada.
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
- Arizona College of Podiatric Medicine, Midwestern University, Glendale, Arizona, USA.
- Weill Cornell Medicine, New York, New York, USA.
- University of Mississippi Medical Center, Jackson, Mississippi, USA.
ORCID-Profile: Aditya K Gupta
Zitieren
APA
Gupta, A. K., Elewski, B., Joseph, W. S., Lipner, S. R., Daniel, C. R., Tosti, A., Guenin, E., & Ghannoum, M. (2024). Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agents. Mycoses, 67(1). https://doi.org/10.1111/myc.13683
Vancouver
Gupta AK, Elewski B, Joseph WS, Lipner SR, Daniel CR, Tosti A, et al. Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agents. Mycoses. 2024;67(1). doi:10.1111/myc.13683
BibTeX
@article{Gupta2024,
author = {Gupta, Aditya K and Elewski, Boni and Joseph, Warren S and Lipner, Shari R and Daniel, C Ralph and Tosti, Antonella and Guenin, Eric and Ghannoum, Mahmoud},
title = {Treatment of onychomycosis in an era of antifungal resistance: Role for antifungal stewardship and topical antifungal agents},
journal = {Mycoses},
year = {2024},
volume = {67},
number = {1},
doi = {10.1111/myc.13683}
}
EUVIMED